Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML on February 15, 2029. There is 1 upcoming event on record.
Cash runway is approximately 18.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| February 15, 2029 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | Trial Milestone | Phase 2/Phase 3 |
Track ATNM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ATNM in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 14, 2026 | 8-K filed: Listing / standard notice, Reg FD disclosure | Corporate | — |
| June 18, 2026 | 8-K filed: Other event | Filing | — |
| May 29, 2026 | 8-K filed: Listing / standard notice, Reg FD disclosure | Corporate | — |
| February 13, 2026 | 8-K filed: Leadership change | Corporate | — |
| November 26, 2025 | 8-K filed: Leadership change | Corporate | — |
| June 15, 2022 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | Trial Milestone | Phase 3 |
| May 15, 2020 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Trial Milestone | Phase 1 |
| November 15, 2018 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | Trial Milestone | Phase 1/Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.